Abstract
BackgroundAs we all know, patients with epithelial ovarian carcinoma have poor prognosis and high recurrence rate. It is critical and challenging to screen out the patients with high risk of recurrence. At present, there are some models predicting the overall survival of epithelial ovarian carcinoma, however, there is no widely accepted tool or applicable model predicting the recurrence risk of epithelial ovarian carcinoma patients. The objective of this study was to establish and verify a nomogram to predict the recurrence risk of EOC.MethodsWe reviewed the clinicopathological and prognostic data of 193 patients with EOC who achieved clinical complete remission after cytoreductive surgery and chemotherapy between January 2003 and December 2013 in Peking University First Hospital. The nomogram was established with the risk factors selected by LASSO regression. The medical data of 187 EOC patients with 5-year standard follow-up in Peking University Third Hospital and Beijing Obstetrics and Gynecology Hospital were used for external validation of the nomogram. AUC curve and Hosmer-Lemeshow test were used to evaluate the discrimination and calibration.ResultsThe nomogram for 3-year recurrence risk was established with FIGO stage, histological grade, histological type, lymph node metastasis status and serum CA125 level at diagnosis. The total score can be obtained by adding the grading values of these factors together. The C statistics was 0.828 [95% CI, 0.764–0.884] and the Chi-square value is 3.6 (P = 0.731 > 0.05) with the training group. When the threshold value was set at 198, the sensitivity, specificity, positive predictive value, negative predictive value and concordance index were 88.8, 67.0, 71.8, 86.3% and 0.558 respectively. In the external validation, the C statistics was 0.803 [95%CI, 0.738–0.867] and the Chi-square value is 11.04 (P = 0.135 > 0.05). With the threshold value of 198, the sensitivity, specificity, positive predictive value, negative predictive value and concordance index of the nomogram were 75.7, 77.0, 83.2, 67.9%, and 0.52 respectively.ConclusionsWe established and validated a nomogram to predict 3-year recurrence risk of patients with EOC who achieved clinical complete remission after cytoreductive surgery and chemotherapy. This nomogram with good discrimination and calibration might be useful for screening out the patients with high risk of recurrence.
Highlights
As we all know, patients with epithelial ovarian carcinoma have poor prognosis and high recurrence rate
The purpose of this study is to identify the influencing factors of recurrence in patients with epithelial ovarian cancer by retrospective cohort study, and to establish a nomogram for predicting recurrence risk, so as to provide a convenient quantitative standard for clinical treatment of patients with EOC and for judging recurrence risk
clinical complete remission (CCR) is defined as: (1) the level of serum carbohydrate antigen 125 (CA125) is within the normal range; and (2) no residual lesions are found by imaging examination after primary treatments
Summary
Patients with epithelial ovarian carcinoma have poor prognosis and high recurrence rate. There are some models predicting the overall survival of epithelial ovarian carcinoma, there is no widely accepted tool or applicable model predicting the recurrence risk of epithelial ovarian carcinoma patients. Patients with primary early-stage ovarian cancer have an overall favorable prognosis, survival after recurrence is poor and comparable to those with recurrent advanced-stage disease [5]. The purpose of this study is to identify the influencing factors of recurrence in patients with epithelial ovarian cancer by retrospective cohort study, and to establish a nomogram for predicting recurrence risk, so as to provide a convenient quantitative standard for clinical treatment of patients with EOC and for judging recurrence risk
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.